Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? | Clinical Cancer Research
Therapy for Advanced or Metastatic Cholangiocarcinoma | OTT
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Debio 1143-SCCHN-301 – Gettysburg Cancer Center
Clinical Trials | Research Study | MedStar Health
Clinical Trials | Research Study | MedStar Health
Systemic therapies for intrahepatic cholangiocarcinoma - Journal of Hepatology
ESMO 2020 Preview, part 2: new and/or notable | BLU Ampersand, Inc.
MTS trials coming soon - BreastCancerTrials.org
Tumor‐agnostic inhibitors in oncology: A new phase for precision medicine - Li - 2020 - Journal of the Chinese Chemical Society - Wiley Online Library
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer - Journal of Hepatology
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality - Cancer Treatment Reviews
Debio 1143-SCCHN-301 – Gettysburg Cancer Center
An introduction to planning for HTA for tumour-agnostic cancer drugs – BresMed
Petros Grivas on Twitter: "@IyerGopa presented on FGFRi in urothelial Ca including fda-approved erdafitinib & other agents, e.g. infigratinib adjuvant trial & Fuze trial for FGFR fusions! Debate ongoing on FGFR alterations
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1 FGFR2 or FGFR3- (FUZE Clinical Trial) | Clinical Research Trial Listing ( Solid Tumor ) ( NCT03834220 )
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - ScienceDirect
Beyond Cancer Type: New Pan-Tumor Targets Emerge
Practical considerations in screening for genetic alterations in cholangiocarcinoma - Annals of Oncology
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma - Cancer Treatment Reviews
Targeting FGFR inhibition in cholangiocarcinoma - Cancer Treatment Reviews
Current and novel therapeutic opportunities for systemic therapy in biliary cancer | British Journal of Cancer
